Review
Copyright ©The Author(s) 2022.
World J Gastroenterol. Sep 28, 2022; 28(36): 5280-5299
Published online Sep 28, 2022. doi: 10.3748/wjg.v28.i36.5280
Table 2 Summary of studies employing a liver-specific drug delivery platform in animal models of alcohol-associated liver disease
Ref.
EtOH feeding model
Platform, route of administration (targeting strategy)
Cargo, paradigm (prevention or treatment)
Physical characterization
Empty particle control
Results
Mechanisms
Size (nm)
Charge (mV)
EE%
In vitro
In vivo
Liposomes
Ponnappa et al[24], 2005Rat chronic (8-10 wk), malesLiposomes, i.v. (passive)S-ODN, preventionN/PN/P10%-14%Yes↓ Liver injury (ALT)-↓ Serum and liver TNFα
Rodriguez et al[28], 2019Mouse acute-on-chronic, malesFusogenic liposomes, i.p. (passive)Rolipram, treatmentN/PN/PN/PNo↓ Liver injury (ALT and AST); ↓ Steatosis; ↓ Oxidative stress; ↓ ER Stress; ↓ Liver cell apoptosis-↑ Hepatic cAMP; ↑ Sod1 and Sod2; ↓ ATF3, Atf4, CHOP, and Gadd34; ↑ Bcl-xl; ↓ Caspase activation
Zhao et al[32], 2016Mouse chronic (8 wk), malesLiposomes, i.v. (passive)Puerarin, PreventionApproximately 182Approximately -29.493.6% ± 1.7%Yes↓ Liver injury (ALT and AST)--
Wu et al[35], 2019Mouse EtOH binge (3 wk), malesLiposomes, i.p. or oral (passive)Astaxanthin, prevention225.0 ± 58.3N/P98%Yes↓ Liver injury (ALT and AST); ↓ Liver fibrosis--
Kumar et al[36], 2019Rat chronic (4 wk via 2 × daily gavage), malesLiposomes, oral (passive)Silymarin, treatmentApproximately 146.9Approximately -47.450.50%No↓ Liver injury (ALT and AST); ↑ Liver function (albumin); ↓ Oxidative stress; ↓ Liver inflammation↓ Apoptosis in Chang cells↑ SOD, GSH, catalase; ↓ TBARS; ↓ IL-6, MPO, nitrite
Yu et al[37], 2021Mouse acute-on-chronic, malesLiposomes, oral (passive)Saikosaponin D, prevention61.66 ± 3.89-37.18 ± 2.8992.28% ± 0.84%Yes↓ Liver injury (ALT and AST); ↓ Steatosis; ↓ Oxidative stress; ↓ Liver inflammation-↓ MDA; ↑ GPx, SOD; ↓ Liver TNFα
Jain et al[38], 2013Rat chronic (8 wk), males and femalesLiposomes, oral (passive)Mangiferin, prevention980 ± 230N/PN/ANo↓ Oxidative stress-↓ MDA; ↑ SOD, GSH, catalase
Exosomes
Gu et al[50], 2021Mouse acute-on-chronic, malesExosomes, from LGG, oral (passive)Endogenous cargo, treatment75 ± 12.7N/PN/AN/A↓ Liver injury (ALT and AST); ↓ Steatosis↓ TNFα, Il-6, IL-1β, Mcp1 in RAW264.7 cells; ↑ AhR activity in gut leukocytes; ↑ ZO-1, occludin, claudin-1, Nrf2 in Caco-2 cellsTnf and Il-1β; ↑ Cyp1a1, IL-22, Reg3b, Reg3g; ↓ Hepatic bacteria; ↓ Liver endotoxin; ↑ Nrf2
Zhuang et al[57], 2015Mouse acute-on-chronic, malesExosomes from ginger, oral (passive)Endogenous cargo, preventionApproximately 340.4Approximately -27.2N/PN/A↓ Liver injury (ALT and AST); ↓ Steatosis-↑ Nrf2 activation
Polymeric nanoparticles
Nag et al[64], 2020Mouse chronic drinking water (16 wk), malesPoly(lactic-co-glycolic acid) nanoparticles, i.p. (passive)Tannic acid/ vitamin e, treatment127.5 ± 1.6-21.2 ± 0.39Tannic acid: 69.7% ± 2.6%; Vitamin E: 63.7% ± 3.2%No↓ Liver injury (ALT, AST, ALP); ↓ Steatosis; ↓ Liver fibrosis; ↓ Oxidative stress; ↓ Liver cell apoptosis; ↓ Liver inflammation; ↑ Cell survival-↑ HDL ↓ LDL; ↓ ROS; ↑ Catalase, GPx, Nrf2; ↓ Bax, bad, cytochrome C, caspase activation; ↑ Bcl2; ↓ TFGβ, IL-6, TNFα, IL-1β, iNOS, COX2; ↓ EGF, EGFR, AKT, PI3K, and mTOR
Natarajan et al[68], 2019Mouse chronic (4 wk), malesPoly l-lysine-polyethylene glycol copolymer nanoparticles, i.p. (passive)Superoxide dismutase, treatmentApproximately 44N/PN/PNo↓ Steatosis; ↓ Liver inflammation↑ SOD1 and ↓ DCF in E47 Hepatoma cells↓ SREBP1; ↑ ADH1; ↓ Cd68, Ccl2, Mmp12, MCP1, and CCR2; ↑ P-AMPKα
Gopal et al[73], 2020Mouse chronic (4 wk), malesPoly l-lysine-polyethylene glycol copolymer nanoparticles, i.p. (passive)Superoxide dismutase 1, treatmentApproximately 44N/PN/PNo↓ Liver injury (ALT); ↓ Steatosis-↓ Plasma and liver MCP-1; ↑ Pparα, Acox1, and Acot1; ↑ Mt2; ↑ SOD1 activity
Zhang et al[75], 2022Mouse chronic (3 wk) + CCL4, femalesChol-PCX nanoparticles, i.v. (passive)PCX and anti-miR-155, TreatmentApproximately 70Approximately 25N/PNo↓ Liver injury (ALT); ↓ Liver fibrosis; ↓ Liver inflammation↓ LPS-induced miR-155 expression in RAW264.7 cells; ↑ CXCR4 antagonism in U20S cellsCol1a1, MMPs, TIMPs, HSC activation; ↓ F480+ cells
Wang et al[76], 2020Mouse EtOH binge (4 d), femalesAngelica sinensis amphipathic cholesteryl hemisuccinate conjugate nanoparticles, i.v. (passive)Curcumin, preventionApproximately 208.4Approximately -2054.7%-86.1%Yes↓ Liver injury (ALT and AST); ↓ Oxidative stress-↑ GSH; ↓ ROS (DHE and MDA)
Bacteria and viruses
Hendrikx et al[83], 2019Mouse acute-on-chronic, male and femalesL. reuteri, oral (intestine-targeted)IL-22, preventionN/AN/AN/AYes (regular L. reuteri)↓ Liver injury (ALT); ↓ Steatosis (ORO and TG); ↓ Liver inflammation; ↑ Intestinal barrier defense-Cxcl1, Cxcl2; ↑ Small intestine Reg3g; ↓ Hepatic bacteria
Satishchandran et al[93], 2018Mouse chronic (5 wk), femalesAAV8, i.v. (active)pri-MiR122, treatmentN/AN/AN/AYes (scrambled miRNA)↓ Liver injury (ALT); ↓ Steatosis (TG, ORO); ↓ Liver inflammation; ↓ Liver fibrosis (Sirius red)-↓ MCP1, IL-1β; ↓ Col1a1